This report aims to provide detailed insights into the Point-of-Care Molecular Diagnostics Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Revenue Growth Analysis:
[233 Pages Report] The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2%
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127
Key Factors Driving Market Growth:
Market growth is driven by the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests.
Key Players Analysis:
Abbott Laboratories (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
bioMérieux SA (France)
Danaher Corporation (US)
Quidel Corporation (US)
QIAGEN N.V. (Netherlands)
Co-Diagnostics, Inc. (US)
Biocartis NV (Belgium)
Meridian Bioscience, Inc. (US)
Thermo Fisher Scientific, Inc. (US)
Lucira Health, Inc. (US)
Cue Health (US)
Driver: Increasing prevalence of infectious diseases and cancer
The increasing prevalence of infectious diseases and cancer in developed and developing regions will positively influence the growth of the point-of-care molecular diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for molecular diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for point-of-care molecular diagnostics during the forecast period.
Opportunity: Growth opportunities in emerging countries
Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the point-of-care molecular diagnostics market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infectious diseases, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=143524127
Regional Growth Analysis:
North America is the largest regional market for point-of-care molecular diagnostics
The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and Rest of the World. In 2020, North America accounted for the largest share of the global point-of-care molecular diagnostics market. The North American point-of-care molecular diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments.
Company Name: MarketsandMarkets
Contact Person: Mr. Aashish Mehra
Email: Send Email
Address:630 Dundee Road Suite 430
State: IL 60062
Country: United States